{
    "id": 1642,
    "fullName": "KIT A829P",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIT A829P lies within the protein kinase domain of the Kit protein (UniProt.org). A829P results in constitutive phosphorylation of Kit, activation of Akt and Erk signaling, and confers acquired resistance to imatinib in culture (PMID: 23582185).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "A829P",
    "createDate": "09/09/2014",
    "updateDate": "09/17/2018",
    "referenceTranscriptCoordinates": {
        "id": 136008,
        "transcript": "NM_000222",
        "gDna": "chr4:g.54736498G>C",
        "cDna": "c.2485G>C",
        "protein": "p.A829P",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1814,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1653,
                "profileName": "KIT A829P"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1811,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1653,
                "profileName": "KIT A829P"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6756,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing KIT A829P demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",
            "molecularProfile": {
                "id": 1653,
                "profileName": "KIT A829P"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1812,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Sutent (sunitinib) (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1653,
                "profileName": "KIT A829P"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1813,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1653,
                "profileName": "KIT A829P"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17530,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT A829P in culture, however, with decreased potency compared to its potency against other KIT variants (PMID: 31205508).",
            "molecularProfile": {
                "id": 1653,
                "profileName": "KIT A829P"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15597,
                    "pubMedId": 31205508,
                    "title": "Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31205508"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6804,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT A829P demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608).",
            "molecularProfile": {
                "id": 23694,
                "profileName": "KIT V560_Y578del KIT A829P"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6915,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",
            "molecularProfile": {
                "id": 24011,
                "profileName": "KIT W557_K558del KIT A829P"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6905,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608).",
            "molecularProfile": {
                "id": 24011,
                "profileName": "KIT W557_K558del KIT A829P"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6910,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",
            "molecularProfile": {
                "id": 24011,
                "profileName": "KIT W557_K558del KIT A829P"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6900,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",
            "molecularProfile": {
                "id": 24011,
                "profileName": "KIT W557_K558del KIT A829P"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9689,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a Gleevec (imatinib)-resistant gastrointestinal stromal tumor cell line harboring a KIT exon 11 mutation and KIT A829P in culture (PMID: 27370604).",
            "molecularProfile": {
                "id": 26978,
                "profileName": "KIT exon11 KIT A829P"
            },
            "therapy": {
                "id": 5163,
                "therapyName": "Imatinib + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7483,
                    "pubMedId": 27370604,
                    "title": "Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370604"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14339,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT A829P and KIT V559D were sensitive to Flumatinib in culture, demonstrating decreased cell proliferation and inhibition of Kit, Erk1/2, and Stat3 phosphorylation (PMID: 24205792).",
            "molecularProfile": {
                "id": 29987,
                "profileName": "KIT V559D KIT A829P"
            },
            "therapy": {
                "id": 3169,
                "therapyName": "Flumatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 663,
                    "pubMedId": 24205792,
                    "title": "Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24205792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14332,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT A829P and KIT V559D were insensitive to Sutent (sunitinib) in culture (PMID: 24205792).",
            "molecularProfile": {
                "id": 29987,
                "profileName": "KIT V559D KIT A829P"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 663,
                    "pubMedId": 24205792,
                    "title": "Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24205792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18611,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Ripretinib (DCC-2618) decreased circulating tumor DNA, resulted in stable disease lasting over 26 months in a patient with gastrointestinal stromal tumor harboring a primary KIT V559_G565del mutation and two acquired resistance mutations, KIT V654A and KIT A829P (PMID: 31085175; NCT02571036).",
            "molecularProfile": {
                "id": 33460,
                "profileName": "KIT V559_G565del KIT V654A KIT A829P"
            },
            "therapy": {
                "id": 4316,
                "therapyName": "Ripretinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1653,
            "profileName": "KIT A829P",
            "profileTreatmentApproaches": [
                {
                    "id": 1493,
                    "name": "KIT Inhibitor",
                    "profileName": "KIT A829P"
                }
            ]
        },
        {
            "id": 23694,
            "profileName": "KIT V560_Y578del KIT A829P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24011,
            "profileName": "KIT W557_K558del KIT A829P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26978,
            "profileName": "KIT exon11 KIT A829P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29987,
            "profileName": "KIT V559D KIT A829P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33460,
            "profileName": "KIT V559_G565del KIT V654A KIT A829P",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 136009,
            "transcript": "XM_005265741",
            "gDna": "chr4:g.54736498G>C",
            "cDna": "c.2485G>C",
            "protein": "p.A829P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136008,
            "transcript": "NM_000222",
            "gDna": "chr4:g.54736498G>C",
            "cDna": "c.2485G>C",
            "protein": "p.A829P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}